Method of treating estrogen responsive breast cancer
The present invention is directed to a method of treating estrogen responsive breast cancer in an individual comprising administering to an individual a therapeutically effective estradiol inhibiting amount of interferon gamma (IFN-γ) and/for a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists. The invention is based upon the surprising discovery that IFN-γ and/or a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists inhibit estradiol production in human adipocytes. This discovery is not only important because it allows for the treatment and/or prevention of estrogen dependent breast cancer using IFN-γ, TNF antagonists or IL-1 antagonist each alone or in combination, but also because IFN-γ and/or TNF antagonists and/or IL-1 antagonists can be used in conjunction with standard anti-estrogen therapy, e.g., tamoxifen and/or aromatase inhibitor, to result in lower estrogen levels than seen with standard anti-estrogen therapy alone. Moreover, the ability to lower estrogen levels by means of the present invention, when combined with standard anti-estrogen therapy, provides an important therapeutic option in that it allows the dose of the anti-estrogen to be reduced, reducing the likelihood of side effects and complications commonly seen with anti-estrogen therapy.
1 . A method of treating estrogen responsive breast cancer in an individual comprising administering a therapeutically effective estradiol inhibiting amount of IFN-γ.
2 . A method of preventing estrogen responsive breast cancer in an individual in a risk of the cancer comprising administering a therapeutically effective estradiol inhibiting amount of IFN-γ.
3 . A method of treating estrogen responsive breast cancer in an individual comprising administering a therapeutically effective estradiol inhibiting amount of a TNF antagonist.
4 . A method of preventing estrogen responsive breast cancer in an individual in a risk of the cancer comprising administering a therapeutically effective estradiol inhibiting amount of a TNF antagonist.
5 . A method of treating estrogen responsive breast cancer in an individual comprising administering a therapeutically effective estradiol inhibiting amount of a combination of IFN-γ and a TNF antagonist.
6 . A method of preventing estrogen responsive breast cancer in an individual in a risk of the cancer comprising administering a therapeutically effective estradiol inhibiting amount of a combination of IFN-γ and a TNF antagonist.
7 . A method of treating estrogen responsive breast cancer in an individual comprising administering a therapeutically effective estradiol inhibiting amount of an IL-1 antagonist.
8 . A method of preventing estrogen responsive breast cancer in an individual in a risk of the cancer comprising administering a therapeutically effective estradiol inhibiting amount of an IL-1 antagonist.
9 . A method of treating estrogen responsive breast cancer in an individual comprising administering a therapeutically effective estradiol inhibiting amount of IFN-γ in combination with an anti-estrogenic agent.
10 . A method of preventing estrogen responsive breast cancer in an individual in a risk of the cancer comprising administering a therapeutically effective estradiol inhibiting amount of IFN-γ in combination with an anti-estrogenic agent.
11 . A method of treating estrogen responsive breast cancer in an individual comprising administering a therapeutically effective estradiol inhibiting amount of a TNF antagonist in combination with a simultaneous, sequential, or separate administration of an anti-estrogenic agent.
12 . A method of preventing estrogen responsive breast cancer in an individual in a risk of the cancer comprising administering a therapeutically effective estradiol inhibiting amount of a TNF antagonist in combination with a simultaneous, sequential, or separate administration of an anti-estrogenic agent.
13 . A method of treating estrogen responsive breast cancer in an individual comprising administering a therapeutically effective estradiol inhibiting amount of IFN- and a TNF antagonist in combination with a simultaneous, sequential, or separate administration of an anti-estrogenic agent.
14 . A method of preventing estrogen responsive breast cancer in an individual in a risk of the cancer comprising administering a therapeutically effective estradiol inhibiting amount of IFN-γ and a TNF antagonist in combination with a simultaneous, sequential, or separate administration of an anti-estrogenic agent.
15 . The method of claim 9 , 10 , 11 , 12 , 13 , or 14 , wherein the anti-estrogenic agent is tamoxifen.
16 . Cancelled
17 . Cancelled
18 . Cancelled
19 . Cancelled
20 . Cancelled
20 . Cancelled
21 . A kit comprising:
i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing estrogen responsive breast cancer in an individual; and ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprisesIFN-γ together with a pharmaceutical acceptable carrier
22 . A kit comprising:
i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing estrogen responsive breast cancer in an individual; and
ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises a TNF antagonist together with a pharmaceutical acceptable carrier
23 . A kit comprising:
ii) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing estrogen responsive breast cancer in an individual; and
ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises a combination of IFN-γ and a TNF antagonist together with a pharmaceutical acceptable carrier
24 . The method of claims 3 , 4 , 5 , 6 , 9 , 10 , 11 or 12 , wherein the TNF antagonist is selected from the group consisting of a tumor necrosis binding protein, a soluble TNF receptor molecule, or an anti-TNF antibody.
25 . The method of claim 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , or 14 further comprising administering of therapeutically effective amount of an IL-1 antagonist.
26 . The method of claim 7 or 8 further comprising administering a therapeutically effective amount of IFN-γ and/or a TNF antagonist.
27 . A kit comprising:
i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing estrogen responsive breast cancer in an individual; and
ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises an IL-1 antagonist together with a pharmaceutical acceptable carrier
28 . The kit of claim 21 , 22 , or 23 wherein said pharmaceutical agent further comprises an IL-1 antagonist.